NCT02743611 2023-10-05Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal MelanomaBellicum PharmaceuticalsPhase 1/2 Terminated4 enrolled 9 charts
NCT02065869 2023-09-29Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell TransplantBellicum PharmaceuticalsPhase 1/2 Terminated187 enrolled 8 charts
NCT03733249 2023-09-26Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical StudyBellicum PharmaceuticalsPhase 1/2 Terminated187 enrolled 8 charts
NCT01875237 2019-07-16Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide GeneM.D. Anderson Cancer CenterPhase 1/2 Terminated3 enrolled 15 charts